ClinicalTrials.gg
Not yet recruitingNCT07098832ZOCDRUpdated Aug 1, 2025

Multimodal Biomarkers in Prediction of Diabetic Retinopathy

An observational study in Diabetic Retinopathy (DR), sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,538
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University — 7 open to participants now, 7 under way, none of them phase 3. Diabetic Retinopathy · Zhongshan Ophthalmic Center, Sun Yat-sen University.

Started
2025
with 2 others
Observational
6 of 10
4 open now
Registered
10th of 10
by date

Among the 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University, this one is one of 3 that started in 2025, is one of 6 observational ones, and was the 10th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

7 of the 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University, or all of them as a file.
02

Study summary

The goal of this observational study is to enroll diabetic patients with diabetic retinopathy and those without diabetic retinopathy, follow up and observe the long-term changes in ocular structure and function of the subjects by comparison, analyze their association with multimodal biomarkers, and explore new methods for the early diagnosis and risk prediction of diabetic retinopathy.

Participants will be followed up over a 5-year follow-up period, during which they will undergo ophthalmic examinations, blood tests, and questionnaires.

03

Conditions studied

  • Diabetic Retinopathy (DR)

Browse trials for

Keywords

  • Diabetic Retinopathy
  • Prospective cohort
  • Multimodal biomarker
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants are planned to be enrolled from the outpatient department of Zhongshan Ophthalmic Center, as well as community populations in Guangzhou and surrounding provinces and cities.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must understand the clinical trial, voluntarily participate, and sign the form.
  • Aged 18-80 years, with no restriction on gender.
  • Healthy control group: No history or diagnosis of diabetes.
  • Diabetic group:

    i) Definite diagnosis of diabetes. Both type 1 and type 2 diabetic patients will be included in this study.

ii) Based on dilated fundus examination, subjects are classified into NDR, NPDR, and PDR groups according to the staging of diabetic retinopathy.

  • Idiopathic epiretinal membrane (iERM) group is set as the control group for intraocular specimen collection and analysis in PDR patients: Funduscopic examination shows gold foil-like reflection or glass membrane-like substance covering the macular area, causing local retinal folds, with or without tortuosity and deformation of small perimacular blood vessels; OCT examination reveals a hyperreflective band on the retinal surface of the macular area; meeting the indications for pars plana vitrectomy combined with internal limiting membrane-epiretinal membrane peeling: visual acuity \< 0.3, or visual acuity > 0.5 but accompanied by progressive vision loss, severe metamorphopsia, diplopia, visual field defect, or other symptoms that significantly affect quality of life, and surgical treatment can be performed if actively requested by the patient; no diagnosis or history of diabetes.

Exclusion criteria

Exclusion Criteria:

  • Complicated with other severe ocular diseases (e.g., glaucoma, age-related macular degeneration, uveitis, etc.).
  • A history of previous ocular surgery.
  • Complicated with severe systemic diseases (e.g., ischemic heart disease, stroke, malignant tumor, and severe liver or kidney diseases) or a history of systemic surgery (e.g., coronary artery bypass grafting, arterial/venous thrombolysis, organ transplantation, etc.).
  • Complicated with cognitive impairment ( score \< 24), mental illness (e.g., schizophrenia, bipolar disorder), or inability to cooperate with questionnaires and ophthalmic examinations due to language comprehension deficits.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,538 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Idiopathic Epiretinal Membrane (iERM) Group

    No additional interventions will be performed. Only the waste fluid generated during the normal surgical procedures of patients requiring surgery will be collected for control purposes (this will not affect surgical safety or prognosis of the patients).

  • Healthy Control Group

    For participants in this group, only anonymous examination data were collected.

  • Proliferative Diabetic Retinopathy (PDR) Group

    Disease group, only collect anonymous examination data, and collect the waste fluid generated during the normal surgical procedures of patients requiring surgery will be collected (this will not affect surgical safety or prognosis of the patients).

  • Non-Proliferative Diabetic Retinopathy (NPDR) Group

    Disease group, for participants in this group, only anonymous examination data were collected.

  • No Diabetic Retinopathy (NDR) Group

    For participants in this group, only anonymous examination data were collected.

06

What researchers measure

Primary outcomes

  1. The progression of diabetic retinopathy during the follow-up period.

    Time frame: From baseline to study completion, an average of 5 years.

Secondary outcomes

  1. Changes in best-corrected visual acuity during the follow-up period.

    Time frame: From baseline to study completion, an average of 5 years.

  2. Changes in ocular functional indicators during the follow-up period.

    Time frame: From baseline to study completion, an average of 5 years.

  3. Changes in ocular fundus structure during follow-up as indicated by optical coherence tomography (OCT) examination.

    Time frame: From baseline to study completion, an average of 5 years.

  4. Changes in ocular fundus blood flow during follow-up by optical coherence as indicated by tomography angiography (OCTA) examination.

    Time frame: From baseline to study completion, an average of 5 years.

  5. Blood and intraocular fluid metabolite concentrations measured by metabolomics during follow-up.

    Time frame: From baseline to study completion, an average of 5 years.

  6. Blood and intraocular fluid protein concentrations measured by proteomics during follow-up.

    Time frame: From baseline to study completion, an average of 5 years.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Dec 2030, 65 months later.

Of 75 non-industry observational studies under Diabetic Retinopathy, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13. This study's planned 65 months is above that.

Counting every sponsor, half of 92 studies reached it within 28 months; a quarter within 12 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Aug 1, 2025
StartEst.
Jul 2025
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07098832
Responsible party
Sponsor
First posted
Aug 1, 2025
Start date
Jul 2025 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 1, 2025

Study contacts

Li Tao, MD, PhD
Contact
litao2@mail.sysu.edu.cn
+86-13724865499
Kangjie Kong, MD, PhD
Contact
kongkj@mail2.sysu.edu.cn
+86-15623426876
Li Tao, MD, PhD
principal investigator · Zhongshan Ophthalmic Center, Sun Yat-sen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion